Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Refractory Multiple Myeloma (RRMM): full-pipeline trial registry
2 of 2 indexed Relapsed Refractory Multiple Myeloma (RRMM) trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Relapsed Refractory Multiple Myeloma (RRMM): 2 US clinical trials tracked, 2 recruiting.
Relapsed Refractory Multiple Myeloma (RRMM) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-refractory-multiple-myeloma-rrmm
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Relapsed Refractory Multiple Myeloma (RRMM) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Refractory Multiple Myeloma (RRMM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Refractory Multiple Myeloma (RRMM) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
NCT05730036
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
NCT06832865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Refractory Multiple Myeloma (RRMM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Refractory Multiple Myeloma (RRMM) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Refractory Multiple Myeloma (RRMM) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Relapsed Refractory Multiple Myeloma (RRMM) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Relapsed Refractory Multiple Myeloma (RRMM) trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Refractory Multiple Myeloma (RRMM) condition card totals 2 registered trials; most-linked intervention Isatuximab SC-OBDS; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.